US Bancorp DE Sells 572 Shares of Core Laboratories Inc. (NYSE:CLB)

US Bancorp DE lessened its position in shares of Core Laboratories Inc. (NYSE:CLB) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,689 shares of the oil and gas company’s stock after selling 572 shares during the period. US Bancorp DE’s holdings in Core Laboratories were worth $198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Disciplined Growth Investors Inc. MN grew its position in shares of Core Laboratories by 446.8% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 4,460,720 shares of the oil and gas company’s stock valued at $90,508,000 after purchasing an additional 3,644,963 shares in the last quarter. Ariel Investments LLC boosted its stake in Core Laboratories by 20.4% during the first quarter. Ariel Investments LLC now owns 10,825,657 shares of the oil and gas company’s stock valued at $184,902,000 after buying an additional 1,837,258 shares during the period. Earnest Partners LLC grew its position in Core Laboratories by 6.3% during the second quarter. Earnest Partners LLC now owns 3,286,438 shares of the oil and gas company’s stock worth $66,682,000 after buying an additional 195,756 shares in the last quarter. Gendell Jeffrey L increased its stake in Core Laboratories by 101.7% in the 1st quarter. Gendell Jeffrey L now owns 326,890 shares of the oil and gas company’s stock worth $5,583,000 after acquiring an additional 164,797 shares during the last quarter. Finally, BWM Planning LLC purchased a new stake in shares of Core Laboratories in the 3rd quarter valued at about $1,205,000. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Stock Performance

Shares of NYSE CLB opened at $19.96 on Friday. The stock has a market cap of $937.12 million, a price-to-earnings ratio of 30.71, a P/E/G ratio of 1.46 and a beta of 2.35. The stock’s 50-day moving average is $18.88 and its 200 day moving average is $19.24. The company has a current ratio of 2.48, a quick ratio of 1.79 and a debt-to-equity ratio of 0.55. Core Laboratories Inc. has a 1-year low of $13.82 and a 1-year high of $25.13.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.21 by $0.04. Core Laboratories had a net margin of 5.83% and a return on equity of 15.84%. The firm had revenue of $134.40 million for the quarter, compared to the consensus estimate of $134.16 million. During the same period last year, the firm posted $0.22 earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Core Laboratories Inc. will post 0.77 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 25th. Stockholders of record on Monday, November 4th will be paid a dividend of $0.01 per share. The ex-dividend date is Monday, November 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.20%. Core Laboratories’s dividend payout ratio (DPR) is currently 6.15%.

Analysts Set New Price Targets

Several research analysts have recently commented on CLB shares. Citigroup cut their price objective on Core Laboratories from $15.00 to $14.00 and set a “sell” rating for the company in a report on Thursday, October 31st. StockNews.com raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Stifel Nicolaus raised their price objective on shares of Core Laboratories from $18.00 to $22.00 and gave the company a “hold” rating in a research report on Friday, July 26th. Two investment analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $17.00.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.